Gibson Dunn, Latham Advise on $958 Million Pharma Deal
Botox-maker Allergan Inc. has agreed to buy Mountain View-based drug company MAP Pharmaceuticals Inc. for $958 million in cash.
This article has been archived, and is no longer available on this website.
Not a LexisNexis® Subscriber?
For questions call 1-877-256-2472 or contact us at email@example.com